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Abstract 1 
Background: Aronia melanocarpa is a rich source of (poly)phenols. Previous 2 
research has demonstrated that berries may provide cardiovascular health benefits 3 
in high-risk populations. However, very few studies have investigated the effects of 4 
daily consumption of dietary achievable amounts of berries in healthy subjects. 5 
Objective: This study aims to investigate the effects of aronia berries on vascular 6 
function and gut microbiota composition in a healthy population. 7 
Methods: A double-blind, placebo-controlled, parallel designed study was conducted 8 
in 66 healthy men randomly allocated to a (poly)phenol rich extract (116 mg, 75 g 9 
berries), a whole fruit powder (12 mg, 10 g berries) or placebo (maltodextrin) for 12 10 
weeks. Flow-mediated dilation, arterial stiffness, blood pressure, heart rate and 11 
serum biochemistry were assessed. Plasma (poly)phenol metabolites were analyzed 12 
using LC-MS. Gut microbiota composition was determined via 16S rRNA 13 
Sequencing in stool samples. 14 
Results: Consumption of aronia whole fruit and extract powder for 12 weeks led to a 15 
significant increase in FMD over control of 0.9 ± 0.4% (95% CI: 0.13, 1.72) and 1.2 ± 16 
0.4% (95% CI: 0.36, 1.97), respectively. Acute improvements in FMD were also 17 
observed 2h after consumption of aronia extract on day 1 (1.1 ± 0.3, p=0.003) and 18 
12 weeks later (1.5 ± 0.4%, p=0.0001). Circulating plasma phenolic metabolites 19 
increased upon consumption of the aronia treatments. Although no changes were 20 
found in gut microbiota diversity, consumption of aronia extract increased the growth 21 
of Anaerostipes (+10.6%, p=0.01), while  aronia whole fruit showed significant 22 
increases in Bacteroides (+193 %, p=0.01). Correlation analysis identified significant 23 
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associations between changes in FMD, aronia-derived phenolic metabolites, and 24 
specific gut microbial genera. 25 
Conclusions: In healthy men, consumption of aronia berry (poly)phenols improved 26 
endothelial function and modulated gut microbiota composition indicating that regular 27 
aronia consumption has the potential to maintain cardiovascular health in individuals 28 
at low risk of cardiovascular disease. 29 
. Introduction  30 
Diet is one of the most important lifestyle factors greatly influencing the incidence and 31 
progression of cardiovascular diseases (CVD) (1). Evidence from epidemiological 32 
studies suggests that high intake of fruit and vegetables reduces the risk of developing 33 
coronary heart disease and stroke (2). This may be due, in part, to bioactive 34 
compounds present in fruits and vegetables, such as (poly)phenols (3). A growing 35 
body of evidence from human intervention studies indicates that chronic consumption 36 
of foods rich in (poly)phenols, such as tea, cocoa and berries, may improve long term 37 
vascular health (4). A limited number of randomized controlled trials (RCTs) have 38 
demonstrated significant improvements in blood lipids, blood pressure and endothelial 39 
function following consumption of berries or other anthocyanin rich foods (5-7). 40 
However, due to the low number of RCTs and large heterogeneity between study 41 
designs, study populations and interventions used, there are some inconsistencies in 42 
the findings (8).  43 
The gut microbiome has an important influence on human health and recent evidence 44 
indicates that it can be modulated by the consumption of (poly)phenols. For example, 45 
consumption of red wine by healthy volunteers over 4 weeks was paralelled with a 46 
significant increase of several microbial communities including Bifidobacterium, 47 
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Bacteroides and Enterococcus (9). Anthocyanin microbial metabolites from red wine 48 
were also previously associated with higher levels of Bifidobacterium, which has been 49 
linked with beneficial health effects (10, 11). Similarly, significant increases in 50 
Bifidobacterium was observed 6-weeks after consumption of anthocyanin-rich wild 51 
blueberry (12). To what extent the modulation of the gut microbiome is important in 52 
the context of the cardiovascular health benefits of polyphenols, is currently not known, 53 
but recent studies suggest that gut microbial metabolism may be a key factor in 54 
explaining health benefits and mechanisms of action of polyphenols (13, 14).  55 
One berry of growing interest is Aronia melanocarpa, as it has one of the highest 56 
(poly)phenol content compared with other fruits (15, 16).  Only a few RCT’s have been 57 
conducted with aronia berries and they have shown that chronic aronia berry 58 
consumption decreased blood pressure in individuals with CVD (17), metabolic 59 
syndrome (18) or at high risk of CVD (17, 19). Whether or not regular aronia 60 
consumption has the potential to maintain and/or improve cardiovascular health in 61 
healthy individuals at low risk of CVD, has not been evaluated. In addition, the effects 62 
of aronia berry consumption on gut microbial ecology have not been previously 63 
investigated. The primary aim of the present study was to investigate the effects of 64 
acute and chronic consumption of dietary achievable amounts of aronia berries in the 65 
form of an encapsulated powder on endothelial function, in a population of young 66 
individuals at low risk of CVD. We also investigated the effects of aronia berry 67 
(poly)phenol consumption on the gut microbiome and which correlations the gut 68 
microbiome have with vascular effects.   69 
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2. Methods 70 
2.1. Intervention Study Subjects 71 
Sixty-six healthy male volunteers aged 18-45 years were recruited from King’s College 72 
London and the surrounding area. Health was ascertained by a routine clinical physical 73 
examination and specific medical history questionnaire. Volunteers with manifest 74 
cardiovascular disease including coronary artery disease, cerebrovascular disease 75 
and peripheral artery disease were excluded (Figure 1). Additional exclusions were: 76 
hypertension (140 mmHg SBP and 90 mmHg DBP), body mass index 30kg/m2, 77 
diabetes mellitus and metabolic syndrome, acute inflammation, terminal renal failure, 78 
malignancies and abnormal heart rhythm (60 or 100 bpm). Subjects were also 79 
excluded if they had allergies to berries or other significant foods, were using 80 
medication or other dietary supplements, smoked an irregular number of cigarettes 81 
per day or were planning to quit in the next 6 months.  82 
 83 
2.2. Study Design  84 
A three-arm, double-blind, parallel, randomized controlled trial was conducted (Figure 85 
1B). Informed consent was obtained and subjects were randomized to the treatments. 86 
We investigated the effects of two formulations of aronia berry capsules on vascular 87 
function compared with a placebo control capsule. Measurements were taken at 88 
baseline and 2 h post-acute consumption, and this was repeated 12 weeks after 89 
chronic capsule consumption.  90 
Once participants were screened and included, they attended two visits, at baseline 91 
and 12 weeks later. Participants were instructed not to alter their usual dietary habits 92 
nor their physical activity throughout the study. Participants were asked to refrain from 93 
eating high (poly)phenol products 24 h prior to the first visit, such as red wine and 94 
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beer, fruits and vegetables, berries, nuts, olive oil, coffee, chocolate or cocoa products 95 
and tea. They were specifically advised to eat dairy products (yoghurt, eggs, milk), 96 
white rice, products containing white flour, meat and fish. Dietary recalls (24 h) were 97 
completed at the start of each visit to monitor the low (poly)phenol diet. Food diaries 98 
and physical activity questionnaires were completed before and during the trial to 99 
ensure their habitual dietary and fluid intake remained consistent. Additionally, 100 
participants were fasted 12 h prior to each visit. Measurements of FMD, peripheral BP, 101 
PWV, AIx as well as blood samples were all taken at baseline (0 h) then, again 2 h 102 
post-acute consumption of one capsule (Figure 2). Stool samples were collected by 103 
the participants, using Omnigene-gut stool kits (DNA Genotek), and stored at -20C at 104 
the beginning of each visit. The volunteers were instructed to take one capsule every 105 
morning with a glass of water. Participants were followed up three times throughout 106 
the 12-week period via phone to ensure no adverse events occurred.  107 
The study investigated acute (0-2 h), chronic (0-12 weeks) and acute on chronic (12 108 
weeks, 2h) effects of aronia berry (poly)phenols. For the purpose of clarity, the next 109 
definitions will be used throughout the text: acute effects (2 h vs. 0 h on day 1), chronic 110 
effects (0 h at week 12 vs. 0 h on day 1) and acute on chronic effects (2 h at week 12 111 
vs. 0 h at week 12). The primary endpoint was endothelial function measured by flow-112 
mediated dilation (FMD) using high-resolution ultrasound upon chronic consumption 113 
of capsules. Secondary endpoints included pulse-wave velocity (PWV), augmentation 114 
index (AIx) and blood pressure (peripheral and central) as determined automatically 115 
by a blood pressure monitoring system and applanation tonometry (Sphygmocor) after 116 
acute and chronic consumption of the treatments. Tertiary outcomes were plasma 117 
glucose, blood lipids, plasma phenolic metabolites and gut microbiota.  118 
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A team of qualified researchers enrolled participants on the study and assigned the 119 
interventions. Participants and researchers administering interventions and assessing 120 
outcomes were blinded to the intervention groups. An independent researcher 121 
generated the random allocation to treatment sequence using a random number 122 
generator with the purpose to allocate a specific number to every volunteer. This way, 123 
information about group allocation remained concealed. When study visits and 124 
analysis of primary outcome were completed, the independent researcher provided 125 
the codes for unblinding and treatment grouping. The study was conducted in 126 
accordance to the guidelines stated in the current revision of the Declaration of 127 
Helsinki. All procedures were approved by King’s College London Ethics Committee 128 
(HR-15/16-3739; clinicaltrials.gov Registration number: NCT03041961). Volunteers 129 
were assessed and data were collected in detailed case report forms between 130 
February and July 2017 in the Metabolic Research Unit at the Department of 131 
Nutritional Sciences of King’s College London.  132 
 133 
2.3. Aronia berry and control capsules  134 
The aronia powders were provided in capsules and manufactured by Naturex-DBS, 135 
LLC (Sagamore, Massachusetts, USA). The “aronia extract” capsules were 136 
concentrated extracts rich in (poly)phenols and processed by the removal of fiber and 137 
organic acids from 75 g aronia berries, containing 116 mg total (poly)phenols 138 
quantified using HPLC (200 mg via Folin Ciocalteu) (Table 1). The “aronia whole fruit” 139 
capsules contained the equivalent to 10 g of the whole aronia berry fruit, and 12 mg 140 
of total (poly)phenols quantified using HPLC (20 mg via Folin Ciocalteu) (Table 1). The 141 
control capsules, matched in appearance to both treatment capsules, contained 142 
maltodextrin and no (poly)phenols. The capsules were all matched in weight, 143 
9 
 
carbohydrates and calories (Supplemental Table 1). Capsules were stored in plastic 144 
bottles with patient randomization number and unique treatment allocation number. 145 
 146 
2.4. Biochemical analyses  147 
Blood samples collected in EDTA/heparin tubes (Greiner Bio-One Ltd., 148 
Gloucestershire, UK) were centrifuged (1700 g; 15 min; 4˚C) immediately after 149 
collection. Plasma samples for (poly)phenol analysis were spiked with 2% formic acid 150 
and frozen at -80C. All clinical chemistry parameters including total cholesterol, LDL 151 
and HDL-cholesterol, TAG (enzymatic photometric assay; RocheDiagnostics), 152 
glucose, HbA1c and whole blood count were analyzed according to standard 153 
procedures (Biochemistry department, King’s College Hospital, Denmark Hill, 154 
London). 155 
 156 
2.5. Dietary assessment of background diet  157 
To assess dietary intake, 7-day food diaries by EPIC (European Prospective 158 
Investigation of Cancer; University of Cambridge) were completed by participants 159 
before the first visit (baseline) and at 11 weeks, before attending the second visit, to 160 
ensure habitual diets did not change during the study period. Participants were 161 
instructed to provide as much detail as possible about all food and drinks consumed. 162 
Average daily macro- and micronutrient composition of participant’s diet were 163 
analyzed with the use of Nutritics (Nutritics Professional Diet Analysis, version 3.74; 164 
Nutritics Ltd). Polyphenol intakes were assessed using the online free database 165 
Phenol-Explorer (http://phenol-explorer.eu). 166 
 167 
2.6. Vascular measurements  168 
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FMD of the brachial artery was measured as previously described (20). Both operator 169 
and participant were blinded during analysis. Briefly, the diameter and flow velocity of 170 
the brachial artery was measured using a 12 MHz transducer (Vivid I, GE healthcare, 171 
Buckinghamshire, UK) and automatic edge-detection software (Brachial Analyser, 172 
Medical imaging applications, Iowa City, USA) yielding standard deviations of mean 173 
differences between repeated measurements of less than 1%. Brachial artery 174 
diameter was measured 2 cm proximal to the elbow. Reactive hyperaemia was 175 
induced by 5 min of distal lower arm occlusion with sphygmomanometric cuff inflated 176 
to 180 mm Hg. Blood flow was recorded at baseline using the Doppler mode. A 177 
forearm blood-pressure cuff was placed distal to the antecubital fossa and inflated to 178 
180 mmHg for 5 min. Diameter was measured at baseline and immediately after cuff 179 
deflation at 20, 40, 60 and 80 sec, the diameter was assessed and FMD calculated as 180 
maximal relative diameter gain relative to baseline. The FMD was expressed as 181 
(diametermax-diameterbaseline)/diameterbaseline x100.  182 
Central BP parameters including AIx were measured by applanation tonometry using 183 
the SphygmoCor® (AtCor medical, Gloucestershire, UK). Via a transfer function, the 184 
pressure waveform of the ascending aorta was synthesized. PWV was determined 185 
using measurements taken at the carotid and femoral artery as previously described 186 
(21). All data analyses was conducted blinded. 187 
 188 
2.7. UHPLC Orbitrap MS analysis of plasma (poly)phenols 189 
Sample preparation and solid phase extraction for plasma (poly)phenol analysis was 190 
performed as described previously (22). The detection of plasma (poly)phenol 191 
metabolites was performed on a ExactiveTM Orbitrap Mass Spectrometer (Thermo 192 
Scientific, CA, USA) after separation on a Accela 1250 pump UHPLC system (Thermo 193 
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Scientific, CA, USA). The autosampler injected of 5 µL of each sample in a Zorbax 194 
Eclipse Plus RRHD column 2.1 × 50 mm, 1.8 m with a compatible Eclipse Plus 195 
guardcolumn 2.1 × 5 mm, 1.8 m (Agilent, Waldbronn, Germany). The mobile phase 196 
consisted of 0.1% HCOOH (solvent A) and acetonitrile with 0.1% HCOOH (solvent B) 197 
in a 10 min gradient program. Quantification analysis of the plasma (poly)phenols was 198 
done using Xcalibur 2.2 (Thermo Scientific, CA, USA). 199 
 200 
2.8 Faecal sample collection and microbiome analysis 201 
Fecal samples were collected in the week before each study visit using 202 
OMNIgene®•GUT self-collection tubes (DNA Genotek, Ottawa, Canada) and were 203 
stored in -20°C until further analysis. Microbiome analysis was performed by Clinical-204 
Microbiomics A/S (Copenhagen, Denmark) as described elsewhere (23). Briefly, Total 205 
microbial DNA was extracted from faeces using the 96-well NucleoSpin Soil DNA 206 
Isolation Kit  (Macherey-Nagel, Düren, Germany). PCR was performed with 16S rDNA 207 
primers S-D-Bact-0341-b-S-17 and reverse primer S-D-Bact-0785-a-A-21 with 208 
Illumina adapters attached (24) in order to target the V3-V4 regions. The following 209 
PCR program was used: 98 °C for 30 sec, 25x (98° C for 10 s, 55 °C for 20 s, 72 °C 210 
for 20 s), 72 °C for 5 min. Sequencing was performed on an Illumina MiSeq desktop 211 
sequencer using the MiSeq Reagent Kit V2 (Illumina, San Diego) for 2x250 bp paired- 212 
end sequencing.  213 
The 64-bit version of USEARCH (25) and mothur (26) were used in combination with 214 
several in-house programs for bioinformatics analysis of the sequence data. Following 215 
tag identification and trimming, all sequences from all samples were pooled. 216 
Sequences were clustered at 97 % sequence similarity. Additional suspected chimeric 217 
OTUs were discarded based on comparison with the Ribosomal Database Project 218 
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classifier training set v9 (27) using UCHIME (28). Taxonomic assignment of OTUs was 219 
done using the method by Wang et al. (29) using the database from the Ribosomal 220 
Database Project. To find modifications in the microbiota structure associated with the 221 
aronia treatments, the samples were also longitudinally analyzed by RandomForest. 222 
Briefly, Random Forest is a powerful classifier that identifies the best subset of 223 
features (here, relative genus abundance) that can discriminate between categories 224 
(time points). In particular, we applied the algorithm to the three groups separetely 225 
(aronia extract, aronia whole fruit and control). The significance in the abundance of 226 
the relevant taxa were validated by Wilcoxon signed-rank tests. 227 
 228 
2.9. Power calculation and statistical analysis  229 
Power calculations were performed for the primary end point: change in FMD 230 
response after chronic consumption. The power was based on the inter-individual 231 
variability for FMD measurement of the operator (SD = 1%). Assuming an 80% power, 232 
and a 0.05 significance level, the total number of subjects required to provide sufficient 233 
power to detect a 1% difference change in FMD in a three-arm parallel study is 60 234 
(n=20 per arm). Assuming a 10% drop out, 22 participants per arm were recruited. 235 
Changes in FMD (%) between control and treatment groups were tested using a one-236 
way ANOVA with Tukey’s post-hoc test. A two-way ANOVA with Tukey’s post-hoc test 237 
was performed on dietary assessment data to test for any significant differences in 238 
time and treatment. One-way ANCOVA with BMI and chronic (poly)phenol intake as 239 
covariates was performed on baseline dietary assessment data to ensure there were 240 
no differences in polyphenol, micro- or macronutrient intakes. Correlations are 241 
presented as Pearson’s r for non-normal distribution and as Spearman for normal 242 
distribution. Statistical analysis were performed with the use of IBM SPSS Statistics 243 
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22.0 (Statistical Product and Service Solutions; IBM Corp) and GraphPad Prism 244 
version 7 for Windows, (GraphPad Software, La Jolla California USA). Statistical 245 
significance is accepted at p<0.05.  246 
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3. Results  247 
3.1. Participant flowchart and baseline characteristics  248 
A total of 84 volunteers were considered for participation in the study, of which 18 were 249 
excluded and 66 were included and randomised into the three intervention groups 250 
(Figure 1). The first study visit started in February and the last study visit ended in 251 
July 2017. A total of 3 follow-up calls were performed per participant between study 252 
visits. Two participants discontinued the study after the first visit, and 64 completed 253 
both visits (drop-out rate of 3%). The baseline characteristics of the different groups 254 
of healthy young men were all within the normal range and no differences were found 255 
between treatment groups (Table 2).  256 
3.2. Safety and tolerance of the interventions  257 
All the treatments were well tolerated and only 4 potential adverse events were 258 
reported over the course of the study, and were considered unrelated to the 259 
treatments: 2 of the participants in the aronia extract group reported unusual tiredness, 260 
1 volunteer in the aronia whole fruit group reported a persistent cough for a few weeks 261 
and in the control group, 1 volunteer reported food poisoning. Supplemental Table 2 262 
shows the 10 safety parameters assessed, which remained in the normal healthy 263 
range after 12 weeks of treatment. 264 
3.4. Dietary assessment of food diaries and evaluation of background diet  265 
Analysis of the 7-day food diaries of study participants revealed no significant 266 
differences in micro- and macronutrient intakes as well as polyphenol intake between 267 
any treatment group prior to the start of the study (Supplemental Table 3). At baseline 268 
participants had an average daily (poly)phenol intake of 531 ± 357 mg, of which 23 ± 269 
8 mg of that being anthocyanins (Supplemental Table 3).  270 
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3.3. Efficacy of aronia interventions on vascular function  271 
Our primary outcome was changes in FMD after 12 weeks chronic supplementation. 272 
Repetitive intake of aronia extract and aronia whole fruit significantly improved FMD 273 
by 1.0 ± 0.2 % and 0.8 ± 0.3 % at baseline of week 12 in comparison to baseline of 274 
day 1, respectively. When compared to control treatment, changes in FMD after 275 
aronia extract and aronia whole fruit consumption were significantly higher by 1.2 % 276 
(95 % CI: 0.36, 1.97) and 0.9 % (95 % CI: 0.13, 1.72), respectively (Figure 2A, 277 
Supplemental Table 4).        278 
Acute improvements in FMD were also investigated with a significant increase in 279 
FMD of 1.4 ± 0.2 % and 1.5 ± 0.2 % observed after 2 h consumption of aronia 280 
extract on day 1 and week 12 in comparison with baseline, respectively (Figure 2B, 281 
Supplemental Table 4). In comparison with control, aronia extract increased 282 
significantly by 1.1 % (95 % CI: 0.37, 1.78) and 1.7 % (95 % CI: 0.62, 2.34) after 2 h  283 
on day 1 and week 12, respectively (Figure 2C). No significant acute FMD changes 284 
with respect to baseline or control were observed for the aronia whole fruit group 285 
(Figure 2, Supplemental Table 4). 286 
No significant differences in the secondary outcomes including peripheral and central 287 
blood pressure, arterial stiffness and blood lipids were observed in any of the 288 
treatment groups (Supplemental Tables 4 and 5). 289 
3.5 Phenolic metabolites increase in plasma after aronia consumption 290 
Detailed targeted metabolomics analysis of plasma samples was performed and 63 291 
phenolic metabolites were quantified at baseline and after consumption of all capsules, 292 
including derivatives of hippuric acids, benzoic acids, hydroxycinnamic acids, 293 
phenylacetic acids, propionic acids, benzaldehydes, catechols, pyrogallols, flavonols 294 
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and valerolactones (Supplemental Figure 1). Most metabolites were present in 295 
nanomolar concentrations, except for hippuric acid, benzoic acid, phenylacetic acid 296 
and 3-(4-hydroxyphenyl)propionic acid, which were present at micromolar levels even 297 
at baseline. The aronia extract group showed increases in total plasma (poly)phenol 298 
concentrations of 166 ± 171 µM and 30 ± 156 µM after 2 h and 12 weeks, respectively. 299 
The whole aronia fruit group also showed total plasma (poly)phenol increases of 43 ± 300 
125 µM and 14 ± 106 µM after 2 h and 12 weeks of consumption, respectively. No 301 
significant differences in total plasma (poly)phenols were found between the three 302 
intervention groups at baseline (One-way ANCOVA with BMI and chronic (poly)phenol 303 
intakes as covariates (Cohen’s f <0.1)), with the exception of phenylacetic acid 304 
(p=0.01), 2-hydroxybenzoic acid (p<0.001), homovanillic acid (p=0.048) and 305 
homovanillic acid sulfate (p=0.04), which were significantly higher in the aronia whole 306 
fruit group (data not shown).   307 
At 2 h postconsumption, 48 compounds increased significantly with respect to baseline 308 
in the aronia extract group (19 hydroxycinnamic acid derivatives, 13 benzoic acids, 5 309 
flavonols, 4 phenylacetic acids, 2 propionic acids, 2 benzaldehydes, 1 hippuric, 1 310 
pyrogallol and 1 valerolactone), while 22 compounds increased significantly after 311 
consumption of the aronia whole fruit (9 benzoic acids, 4 hydroxycinnamic acids, 3 312 
phenylacetic acids, 2 flavonols, 2 benzaldehydes, 1 hippuric and 1 pyrogallol 313 
derivative).  Only one compound, 1-Methylpyrogallol-O-sulfate, increased significantly 314 
after consumption of the control capsule.   315 
Chronic intake of the capsules for 12 weeks led to significantly increased fasting 316 
plasma levels of 18 compounds in the aronia extract group, 10 compounds in the 317 
whole berry group and 4 compounds in the control group. The increases observed in 318 
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the aronia berry groups were predominantly driven by phenylacetic acids, benzoic 319 
acids, hydroxycinnamic acids, flavonols and benzaldehydes (Figure 3). 320 
On week 12, plasma phenolic metabolites also increased significantly 2 h post-321 
consumption of aronia extract (2 hippuric acids, 5 benzoic acids, 7 hydroxycinnamic 322 
acid derivatives, 2 phenylacetic acids, 2 benzaldehydes, 2 flavonols, 1 propionic acid 323 
and 1 valerolactone) and aronia whole fruit (2 hippuric acids, 5 benzoic acids, 6 324 
hydroxycinnamic acid derivatives, 2 benzaldehydes, 1 phenylacetic acid, 1 propionic 325 
acid, 1 catechol derivative and 1 flavonol), while only 1 compound (phenylacetic acid) 326 
increased in the control group.  327 
Correlation analysis between changes in plasma metabolites and changes in FMD 328 
with respect to baseline revealed significant correlations in 20 metabolites after aronia 329 
extract consumption and in 5 metabolites after consumption of the whole fruit 330 
treatment (Table 3).  331 
3.6 Effects of aronia berry consumption on gut microbial abundancy 332 
Faecal samples were taken on the first and last day of the study to conduct genomic 333 
analysis of microbial communities. To test the hypothesis that aronia supplements can 334 
lead the human gut microbiome to different configurations, we first analyzed the overall 335 
microbiome diversity - described in terms of the diversity within a sample, (i.e. alpha 336 
diversity) and between samples (beta diversity). Microbial diversity was very high and 337 
not significant in any of the treatment groups after aronia intake (data not shown). Next 338 
we visualized the data on a broad scale by principal component analysis and observed 339 
that Anaerostipes and Bifidobacterium clustered towards opposite directions as 340 
compared to Faecalibacterium and Clostridium genera (Supplemental Figure 2). 341 
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Random Forests was applied to predict the bacterial genera that would discriminate 342 
between the different treatment groups. Treatment-discriminatory bacterial genera 343 
were identified with distinctive modifications in their relative abundances, which were 344 
validated by Wilcoxon signed-rank tests with the following results: the aronia extract 345 
group had a significant higher abundance of Anaerostipes (+10.6%, p=0.01), and the 346 
aronia whole fruit group showed significant increases in Bacteroides (+193 %, p=0.01), 347 
whereas Clostridium XiVb was significantly higher (+2.5 %, p=0.01) after placebo 348 
treatment (Figure 4). The difference of the changes in % abundancy were also 349 
calculated between treatment groups and revealed significant higher increases in 350 
Anaerostipes  (21 %, p=0.04) when comparing aronia extract group to placebo group 351 
(Figure 4).  352 
3.7 Correlations between gut microbiome, plasma (poly)phenol metabolites and FMD 353 
To explore the relationship between the gut microbiome and (poly)phenol metabolism, 354 
correlation heatmaps were created (Figure 5). The change in a subset of metabolites 355 
measured in circulation after 12-week intake of extract  capsules (corrected from 356 
control) were correlated with the corresponding changes in gut microbial genera 357 
abundances (adjusted from control) (Figure 5A). In a similar way, a correlation 358 
heatmap was performed using data from whole fruit groups (adjusted from control) 359 
(Figure 5B). Figure 4 shows that significant correlations were found in both matrices, 360 
with more significant associations after intake of the extract compared to whole fruit. 361 
The highest number of associations between gut microbial genera and plasma 362 
(poly)phenol metabolites were found for Prevotella (correlated with 9 plasma 363 
metabolites), Dialister (correlation with 8 plasma metabolites), Desulfovibrio 364 
(correlated with 7 metabolites) and Bifidobacteria (correlated with 6 plasma 365 
metabolites),upon intake of aronia extract (Figure 5A). Following aronia whole fruit 366 
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consumption, Lactobacillus and Dialister were correlated with 3 and 4 aronia 367 
metabolites respectively (Figure 5B).  368 
To investigate the link between the microbiome and vascular health we performed a 369 
correlation analysis between FMD results and the select gut microbial genera. More 370 
specifically, independent correlations (for extract (n=23) and whole fruit (n=23)) were 371 
performed between changes from baseline in FMD (corrected from control) and 372 
changes in microbial abundancies (adjusted from control). The results show that for 373 
the extract group FMD was significantly correlated with Dialister (spearman ρ: 0.42), 374 
Phascolarctobacterium (spearman ρ: -0.45) and Roseburia (spearman ρ: -0.45). No 375 
significant correlations were found in the aronia whole fruit group. 376 
377 
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4. Discussion 378 
In the present study, daily consumption of aronia whole fruit powder or a polyphenol 379 
rich aronia extract for 12 weeks significantly improved endothelial function in a group 380 
of healthy young men. The amounts used in the present study are equivalent to 381 
consuming 10 and 75 g of aronia fruit per day, which is an amount that can be easily 382 
achieved within a normal diet. The magnitude of the effects (changes in FMD of 0.9-383 
1.2% in comparison with control) are similar to the changes obtained after chronic 384 
consumption of other polyphenol rich foods such as cocoa (3, 30-33). Such 385 
improvements in vascular function are clinically relevant, as an improvement in FMD 386 
of 1% was associated with a decrease in 8 to 10% overall CVD risk over 4 years in a 387 
recent meta-analysis of 23 randomized controlled trials (34).  388 
Consumption of both aronia treatments for 12 weeks led to improvements in FMD of 389 
the same magnitude, despite the low (poly)phenol content of the aronia whole fruit in 390 
comparison with the aronia extract. One possible explanation for this is the presence 391 
of non-extractable (poly)phenols bound to fiber in the aronia whole fruit capsules. It 392 
has been reported that non-extractable (poly)phenols constitute approximately 50% of 393 
the total (poly)phenol content in fruits (34), and 95% of those non-extractable 394 
compounds are released from the food matrix by microbial fermentation and the action 395 
of intestinal digestive enzymes (35). Thus, non-extractable (poly)phenols could be 396 
responsible for the significant increases in phenolic metabolites seen in the plasma of 397 
volunteers after the aronia whole fruit consumption, and potentially responsible for the 398 
improvements in vascular function after chronic consumption of the capsules. We 399 
cannot discard though that there may be other bioactive components in the whole fruit 400 
powder, such as fibers, that could contribute to the effect on FMD and to the prebiotic 401 
activity of this treatment. However, the amounts of fiber present in the whole fruit 402 
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capsules are low in comparison with habitual dietary intake, and unlikely to exert 403 
effects on their own, but it is possible that they may act synergistically with the 404 
polyphenols leading to beneficial effects. Given that the aronia extract had no fiber 405 
and exerted similar effects on FMD than the whole fruit, this suggests that the 406 
polyphenols from aronia may be the most likely compounds responsible for the 407 
beneficial effects observed. Further work is warranted in this area.  408 
Acute improvements in FMD were also observed 2 h after consumption of aronia 409 
extract, but not after aronia whole fruit capsules. A comprehensive targeted 410 
metabolomic analysis revealed a 4 times higher significant increase in plasma 411 
phenolic metabolites after acute consumption of the aronia extract in comparison with 412 
the aronia whole fruit, which may explain why the effects on FMD were only significant 413 
after consumption of the aronia extract. A total of 24 metabolites correlated 414 
significantly upon intake of aronia extract with the most abundant ones being 415 
conjugated hydroxycinnamic acids and benzoic acids, such as isoferulic, 416 
dihydroferulic acids or hydroxybenzoic acids. This data agrees with our previous work 417 
showing significant associations between circulating plasma phenolic acid metabolites 418 
and improvements in endothelial function (20, 35, 36). Although the exact mechanisms 419 
of action are not known, dietary (poly)phenols may mediate improvements in vascular 420 
function by increasing the steady-state level of NO in endothelial cells, for example by 421 
inhibiting NADPH oxidase (37, 38). We have previously demonstrated that NADPH 422 
oxidase activity significantly decreased after acute consumption of blueberry 423 
(poly)phenols, and such inhibition correlated with improvements in FMD and plasma 424 
levels of phenolic metabolites (18). Aronia (poly)phenols may act in a similar way as 425 
the phenolic metabolites correlating with the FMD reported here have similar 426 
structures and may also be able to act as NADPH inhibitors (35, 18). The chronic 427 
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effects observed here could also be mediated via gene expression alterations, which 428 
was shown by few studies addressing the molecular mechanisms-of-action of 429 
(poly)phenols in vitro and in vivo using nutrigenomic approaches (39, 40).  430 
Our results also showed that aronia berry consumption can modulate the gut 431 
microbiome. A significant increase in Anaerostipes abundance was found after the 432 
aronia extract consumption. It is suggested that the Anaerostipes genus plays an 433 
important functional role in the gut ecosystem due to the ability to produce butyrate 434 
from lactate (41). Butyrate was associated with beneficial effects in various diseases 435 
such as genetic metabolic diseases, hypercholesterolemia, insulin resistance, and 436 
ischemic stroke and colon cancer (42). Bacteroides had a significant increase of 437 
abundance after intake of the aronia whole fruit capsules. Similarly, a study showed 438 
significant increases in Bacteroides when healthy volunteers consumed red wine 439 
(poly)phenols for one month (9). A few studies have associated Bacteroides with 440 
improved health. For example, it was found that Bacteroides abundance increased in 441 
obese individuals that lost weight (43) and decreased in patients with inflammatory 442 
bowel disease (44), but also that polysaccharide A, which is produced by Bacteroides, 443 
could prevent inflammatory bowel disease in animals (45). In agreement with the 444 
findings above, other (poly)phenol-rich food sources have shown increased numbers 445 
of Enterococcus, Prevotella, Bacteroides, Bifidobacterium, Bacteroides uniformis, 446 
Eggerthella lenta, and Blautia (46, 47). 447 
Over half of the quantified plasma phenolic acids in the current study were previously 448 
identified as gut microbial breakdown products (48, 49). Although the importance of 449 
the gut microbiome on the metabolism of polyphenols has been long recognized, to 450 
date little is known regarding which bacteria is responsible for the production of 451 
individual metabolites. To explore such relationships, we correlated bacterial genera 452 
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with plasma (poly)phenol metabolites  of volunteers after consumption of the aronia 453 
treatments. A significant number of correlations were found, in particular in volunteers 454 
who consumed the aronia extract. For example, Prevotella, Bifidobacteria, Dialister 455 
and Desulfovibrio showed the highest number of associations with plasma 3-456 
hydroxyhippuric acid, benzoic acids, cinnamic acids and  phenylacetic acids. 457 
Prevotella and Lactobacillus were also significantly associated with ferulic acid, 458 
dihydrocaffeic acid, or isoferulic acid-3-O-sulfate, suggesting that several families of 459 
gut microbes are involved in the metabolism of aronia berry (poly)phenols. This is 460 
supported by evidence showing that gut microbes catabolize (poly)phenols into 461 
smaller phenolic acids including hydroxycinnamic acids, phenylacetic acids, and 462 
phenylpropionic acids (50).  463 
The correlation analysis between gut microbial genera and FMD revealed significant 464 
associations for Dialister, Phascolarctobacterium and Roseburia, which also showed 465 
correlations with plasma phenolic acids such as isoferulic acid-3-O-β-D-glucuronide, 466 
gallic acid, dihydrocaffeic acid, and isoferulic acid-3-O-sulfate (Figure 5A). These 467 
bacteria are also capable to produce short chain fatty acids such as propionic and 468 
butyric acid (51, 52). Evidence suggests that these short chain fatty acids might have 469 
a beneficial impact on gut barrier, glucose homeostasis, obesity and vascular health 470 
(53, 54). Indeed, it was recently shown that propionic acid could protect against 471 
hypertensive cardiovascular damage (55). The link between aronia (poly)phenols, gut 472 
microbiome and improved vascular function could therefore be linked to the ability of 473 
gut microbes such as Dialister to produce potentially bioactive phenolic metabolites 474 
and short chain fatty acids (propionic and butyric acids) that could be beneficial for 475 
vascular health.   476 
 477 
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Our work is limited by the small number of participants and further studies with a larger 478 
number of participants are needed to confirm our findings. Another notable limitation 479 
of this work is that the study population consisted of a group of healthy young men. 480 
Therefore, our findings cannot be directly extrapolated to all segments of the general 481 
population. The study also has notable strengths. This is reflected by the use of gold 482 
standard techniques for measuring vascular function, a double blind RCT design, and 483 
an extensive metabolomics analysis of plasma (poly)phenols in tandem with the 484 
primary outcome made it possible to correlate plasma levels with FMD as well as with 485 
gut microbial genera.  486 
In conclusion, our present data indicate that consumption of dietary achievable 487 
amounts of Aronia berries can lead to clinically relevant improvements in endothelial 488 
function. Furthermore, we linked plasma phenolic metabolites to vascular benefits and 489 
changes in gut microbial populations. Our results indicate that consumption of aronia 490 
berry (poly)phenols as part of a balanced and healthy diet may help to maintain 491 
cardiovascular health in young male individuals at low risk of CVD.  492 
 
Acknowledgements 
The study was performed at the Department of Nutritional Sciences of King’s College 
London. Each author contributed significantly to the research laid down in this 
manuscript. ARM and EF designed the study. GI and ARM coordinated the study. GI, 
VD, JY, EW and CR recruited all participants and conducted the day to day clinical 
visits. GI performed the analysis of plasma (poly)phenols using LC-MS. Faecal 
samples were analysed by Clinical Microbiomics. Statistical analysis and data 
interpretation were performed by GI, ARM, and MLS. Microbiome data analysis was 
25 
 
performed by Clinical Microbiomics, SR, AC and GI. DC and GI analyzed food diaries. 
GI, ARM, MLS, and EW contributed to writing the manuscript. EF is employed by 
Naturex Inc. Naturex Inc. is an international group specializing in plant extraction and 
natural ingredients for food, health and beauty sectors.There are no other conflict of 
interest to declare.  
26 
 
References 
1. World Health Organisation. The top 10 causes of death worldwide. 
2017:Internet: http://www.who.int/mediacentre/factsheets/fs310/en/ (accessed 
5 November 2018). 
2. Zhan J, Liu Y-J, Cai L-B, Xu F-R, Xie T, He Q-Q. Fruit and vegetable 
consumption and risk of cardiovascular disease: A meta-analysis of 
prospective cohort studies. Crit Rev Food Sci Nutr 2017;57(8):1650-63. 
3. Grassi D, Desideri G, Necozione S, di Giosia P, Barnabei R, Allegaert L, 
Bernaert H, Ferri C. Cocoa consumption dose-dependently improves flow-
mediated dilation and arterial stiffness decreasing blood pressure in healthy 
individuals. J Hypertens 2015;33(2):294-303. 
4. Hartley L, Igbinedion E, Holmes J, Flowers N, Thorogood M, Clarke A, 
Stranges S, Hooper L, Rees K. Increased consumption of fruit and vegetables 
for the primary prevention of cardiovascular diseases. Cochrane Database 
Syst Rev 2013(6):Cd009874. 
5. Oszmiański J, Wojdylo A. Aronia melanocarpa phenolics and their antioxidant 
activity. Eur Food Res Technol 2005;221(6):809-13. 
6. Zheng W, Wang SY. Oxygen Radical Absorbing Capacity of Phenolics in 
Blueberries, Cranberries, Chokeberries, and Lingonberries. J Agric Food 
Chem 2003;51(2):502-9. 
7. Dohadwala MM, Holbrook M, Hamburg NM, Shenouda SM, Chung WB, Titas 
M, Kluge MA, Wang N, Palmisano J, Milbury PE, et al. Effects of cranberry 
juice consumption on vascular function in patients with coronary artery 
disease. Am J Clin Nutr 2011;93(5):934-40. 
8. Fairlie-Jones L, Davison K, Fromentin E, Hill A. The Effect of Anthocyanin-
Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review 
and Meta-Analysis of Randomised Controlled Trials. Nutrients 2017;9(8):908. 
9. Queipo-Ortuno MI, Boto-Ordonez M, Murri M, Gomez-Zumaquero JM, 
Clemente-Postigo M, Estruch R, Cardona Diaz F, Andres-Lacueva C, 
Tinahones FJ. Influence of red wine polyphenols and ethanol on the gut 
microbiota ecology and biochemical biomarkers. Am J Clin Nutr 
2012;95(6):1323-34. 
10. Boto-Ordonez M, Urpi-Sarda M, Queipo-Ortuno MI, Tulipani S, Tinahones FJ, 
Andres-Lacueva C. High levels of Bifidobacteria are associated with 
increased levels of anthocyanin microbial metabolites: a randomized clinical 
trial. Food Funct 2014;5(8):1932-8. 
11. Saulnier DM, Kolida S, Gibson GR. Microbiology of the human intestinal tract 
and approaches for its dietary modulation. Curr Pharm Des 
2009;15(13):1403-14. 
12. Vendrame S, Guglielmetti S, Riso P, Arioli S, Klimis-Zacas D, Porrini M. Six-
week consumption of a wild blueberry powder drink increases bifidobacteria in 
the human gut. J Agric Food Chem 2011;59(24):12815-20. 
13. Gonzalez-Sarrias A, Garcia-Villalba R, Romo-Vaquero M, Alasalvar C, Orem 
A, Zafrilla P, Tomas-Barberan FA, Selma MV, Espin JC. Clustering according 
to urolithin metabotype explains the interindividual variability in the 
improvement of cardiovascular risk biomarkers in overweight-obese 
individuals consuming pomegranate: A randomized clinical trial. Mol Nutr 
Food Res 2017;61(5). 
27 
 
14. Espin JC, Gonzalez-Sarrias A, Tomas-Barberan FA. The gut microbiota: A 
key factor in the therapeutic effects of (poly)phenols. Biochem Pharmacol 
2017;139:82-93. 
15. Feliciano R, Istas G, Heiss C, Rodriguez-Mateos A. Plasma and Urinary 
Phenolic Profiles after Acute and Repetitive Intake of Wild Blueberry. 
Molecules 2016, Vol 21, Page 1120 2016;21(9):1120-. 
16. Rodriguez-Mateos A, Hezel M, Aydin H, Kelm M, Lundberg JO, Weitzberg E, 
Spencer JP, Heiss C. Interactions between cocoa flavanols and inorganic 
nitrate: additive effects on endothelial function at achievable dietary amounts. 
Free Radic Biol Med 2015;80:121-8. 
17. Loo B-M, Erlund I, Koli R, Puukka P, Hellström J, Wähälä K, Mattila P, Jula A. 
Consumption of chokeberry (Aronia mitschurinii) products modestly lowered 
blood pressure and reduced low-grade inflammation in patients with mildly 
elevated blood pressure. Nutr Res 2016;36(11):1222-30. 
18. Broncel M, Kozirog M, Duchnowicz P, Koter-Michalak M, Sikora J, 
Chojnowska-Jezierska J. Aronia melanocarpa extract reduces blood pressure, 
serum endothelin, lipid, and oxidative stress marker levels in patients with 
metabolic syndrome. Med Sci Monit 2010;16(1):Cr28-34. 
19. Kardum N, Milovanovic B, Savikin K, Zdunic G, Mutavdzin S, Gligorijevic T, 
Spasic S. Beneficial Effects of Polyphenol-Rich Chokeberry Juice 
Consumption on Blood Pressure Level and Lipid Status in Hypertensive 
Subjects. J Med Food 2015;18(11):1231-8. 
20. Rodriguez-Mateos A, Rendeiro C, Bergillos-Meca T, Tabatabaee S, George 
TW, Heiss C, Spencer JP. Intake and time dependence of blueberry 
flavonoid-induced improvements in vascular function: a randomized, 
controlled, double-blind, crossover intervention study with mechanistic 
insights into biological activity. Am J Clin Nutr 2013;98(5):1179-91. 
21. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De 
Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FUS, Protogerou AD, et 
al. Expert consensus document on the measurement of aortic stiffness in daily 
practice using carotid-femoral pulse wave velocity. J Hypertens 
2012;30(3):445-8. 
22. Feliciano RP, Mecha E, Bronze MR, Rodriguez-Mateos A. Development and 
validation of a high-throughput micro solid-phase extraction method coupled 
with ultra-high-performance liquid chromatography-quadrupole time-of-flight 
mass spectrometry for rapid identification and quantification of phenolic 
metabolites i. J Chromatogr A 2016;1464:21-31. 
23. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, 
Jensen BA, Forslund K, Hildebrand F, Prifti E, Falony G. Human gut microbes 
impact host serum metabolome and insulin sensitivity. Nature 
2016;535(7612):376. 
24. Klindworth A, Pruesse E, Schweer T, Peplies J, Quast C, Horn M, Glöckner 
FO. Evaluation of general 16S ribosomal RNA gene PCR primers for classical 
and next-generation sequencing-based diversity studies. Nucleic Acids Res 
2013;41(1):e1-e. 
25. Edgar RC. UPARSE: highly accurate OTU sequences from microbial 
amplicon reads. Nat Methods 2013;10(10):996-8. 
26. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, 
Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, et al. Introducing mothur: 
open-source, platform-independent, community-supported software for 
28 
 
describing and comparing microbial communities. Appl Environ Microbiol 
2009;75(23):7537-41. 
27. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-
Alfaro A, Kuske CR, Tiedje JM. Ribosomal Database Project: data and tools 
for high throughput rRNA analysis. Nucleic Acids Res 2014;42(Database 
issue):D633-D42. 
28. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves 
sensitivity and speed of chimera detection. Bioinformatics 2011;27(16):2194-
200. 
29. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naïve Bayesian Classifier for Rapid 
Assignment of rRNA Sequences into the New Bacterial Taxonomy. Appl 
Environ Microbiol 2007;73(16):5261-7. 
30. Heiss C, Sansone R, Karimi H, Krabbe M, Schuler D, Rodriguez-Mateos A, 
Kraemer T, Cortese-Krott MM, Kuhnle GG, Spencer JP, et al. Impact of cocoa 
flavanol intake on age-dependent vascular stiffness in healthy men: a 
randomized, controlled, double-masked trial. Age (Dordr) 2015;37(3):9794. 
31. Sansone R, Rodriguez-Mateos A, Heuel J, Falk D, Schuler D, Wagstaff R, 
Kuhnle GG, Spencer JP, Schroeter H, Merx MW, et al. Cocoa flavanol intake 
improves endothelial function and Framingham Risk Score in healthy men 
and women: a randomised, controlled, double-masked trial: the Flaviola 
Health Study. Br J Nutr 2015;114(8):1246-55. 
32. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, Kwak HK, 
Milbury P, Paul SM, Blumberg J, et al. Flavonoid-rich dark chocolate improves 
endothelial function and increases plasma epicatechin concentrations in 
healthy adults. J Am Coll Nutr 2004;23(3):197-204. 
33. Khan F, Ray S, Craigie AM, Kennedy G, Hill A, Barton KL, Broughton J, Belch 
JJ. Lowering of oxidative stress improves endothelial function in healthy 
subjects with habitually low intake of fruit and vegetables: a randomized 
controlled trial of antioxidant- and polyphenol-rich blackcurrant juice. Free 
Radic Biol Med 2014;72:232-7. 
34. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and 
cardiovascular risk prediction: a systematic review with meta-analysis. Intern J 
Cardio 2013;168(1):344-51. 
35. Rodriguez-Mateos A, Feliciano RP, Boeres A, Weber T, dos Santos CN, 
Ventura MR, Heiss C. Cranberry (poly)phenol metabolites correlate with 
improvements in vascular function: A double-blind, randomized, controlled, 
dose-response, crossover study. Mol Nutr and Food Res 2016:1-11. 
36. Istas G, Declerck K, Pudenz M, Szic KSV, Lendinez-Tortajada V, Leon-Latre 
M, Heyninck K, Haegeman G, Casasnovas JA, Tellez-Plaza M, et al. 
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as 
blood surrogate markers for cardiovascular disease. Sci Rep 2017;7(1):5120. 
37. Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated flavanols and 
other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem 
Biophys 2008;469(2):209-19. 
38. Heiss C, Rodriguez-Mateos A, Kelm M. Central Role of eNOS in the 
Maintenance of Endothelial Homeostasis. Antioxidants & Redox Signaling 
2015;22(14):1230-42. 
39. Monfoulet LE, Mercier S, Bayle D, Tamaian R, Barber-Chamoux N, Morand 
C, Milenkovic D. Curcumin modulates endothelial permeability and monocyte 
29 
 
transendothelial migration by affecting endothelial cell dynamics. Free Radic 
Biol Med 2017;112:109-20. 
40. Krga I, Milenkovic D, Morand C, Monfoulet LE. An update on the role of 
nutrigenomic modulations in mediating the cardiovascular protective effect of 
fruit polyphenols. Food Funct 2016;7(9):3656-76. 
41. Muñoz-Tamayo R, Laroche B, Walter É, Doré J, Duncan SH, Flint HJ, Leclerc 
M. Kinetic modelling of lactate utilization and butyrate production by key 
human colonic bacterial species. FEMS Microbiol Ecol 2011;76(3):615-24. 
42. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential 
beneficial effects of butyrate in intestinal and extraintestinal diseases. World J 
Gastroenterol 2011;17(12):1519-28. 
43. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An 
obesity-associated gut microbiome with increased capacity for energy 
harvest. Nature 2006;444(7122):1027-31. 
44. Zhou Y, Zhi F. Lower Level of Bacteroides in the Gut Microbiota Is Associated 
with Inflammatory Bowel Disease: A Meta-Analysis. BioMed Research 
International 2016;2016:9. 
45. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents 
intestinal inflammatory disease. Nature 2008;453(7195):620-5. 
46. Moreno-Indias I, Sanchez-Alcoholado L, Perez-Martinez P, Andres-Lacueva 
C, Cardona F, Tinahones F, Queipo-Ortuno MI. Red wine polyphenols 
modulate fecal microbiota and reduce markers of the metabolic syndrome in 
obese patients. Food Funct 2016;7(4):1775-87. 
47. Barroso E, Sanchez-Patan F, Martin-Alvarez PJ, Bartolome B, Moreno-
Arribas MV, Pelaez C, Requena T, van de Wiele T, Martinez-Cuesta MC. 
Lactobacillus plantarum IFPL935 favors the initial metabolism of red wine 
polyphenols when added to a colonic microbiota. J Agric Food Chem 
2013;61(42):10163-72. 
48. Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and 
chemopreventive ellagitannins from strawberries, raspberries, walnuts, and 
oak-aged wine in humans: identification of biomarkers and individual 
variability. J Agric Food Chem 2005;53(2):227-35. 
49. Gross G, Jacobs DM, Peters S, Possemiers S, van Duynhoven J, Vaughan 
EE, van de Wiele T. In vitro bioconversion of polyphenols from black tea and 
red wine/grape juice by human intestinal microbiota displays strong 
interindividual variability. J Agric Food Chem 2010;58(18):10236-46. 
50. Selma MaV, Espín JC, Tomás-Barberán FA. Interaction between Phenolics 
and Gut Microbiota: Role in Human Health. J Agric Food Chem 
2009;57(15):6485-501. 
51. Tanca A, Abbondio M, Palomba A, Fraumene C, Manghina V, Cucca F, 
Fiorillo E, Uzzau S. Potential and active functions in the gut microbiota of a 
healthy human cohort. Microbiome 2017;5(1):79-. 
52. Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F. From Dietary Fiber 
to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 
2016;165(6):1332-45 
53 Tomas-Barberan FA, Selma MV, Espin JC. Interactions of gut microbiota with 
dietary polyphenols and consequences to human health. Curr Opin Clin Nutr 
Metab Care 2016;19(6):471-6. 
30 
 
54. Chambers ES, Preston T, Frost G, Morrison DJ. Role of Gut Microbiota-
Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health. 
Current nutrition reports 2018;7(4):198-206. 
55. Bartolomaeus H, Balogh A, Yakoub M, Homann S, Marko L, Hoges S, 
Tsvetkov D, Krannich A, Wundersitz S, Avery EG, et al. The Short-Chain 
Fatty Acid Propionate Protects from Hypertensive Cardiovascular Damage. 
Circulation 2018. 
 
 
31 
 
Tables 
Table 1.  (Poly)phenol content of intervention capsule 
Per capsule (500 mg)  
Extract Whole fruit Control 
Mean ± SD 
Flavonols (mg) 35 ± 0.3 2.6 ± 0.1 0 ± 0 
Quercetin (µg) 1625 ± 395 575 ± 430 0 ± 0 
Quercetin-3-glucoside (µg) 8879 ± 970 534 ± 33 0 ± 0 
Quercetin-3-galactoside (µg) 7859 ± 68 816 ± 42 0 ± 0 
Quercetin-3-rhamnoside (µg) 9 ± 1.5 0 ± 0 0 ± 0 
Quercetin-3-rutinoside (µg) 15797 ± 613 610 ± 20 0 ± 0 
Kaempferol (µg) 18 ± 19 27 ± 30 0 ± 0 
Kaempferol-3-glucoside (µg) 229 ± 21 0 ± 0 0 ± 0 
Myricetin (µg) 6.5 ± 7 2.5 ± 2.5 0 ± 0 
Myricetin-3-glucoside (µg) 76 ± 8.5 0 ± 0 0 ± 0 
Isorhamnetin (µg) 71 ± 24 32 ± 18 0 ± 0 
Hesperetin (µg) 1.5 ± 1.5 1 ± 1.5 0 ± 0 
Naringenin (µg) 5.5 ± 1 2 ± 0.5 0 ± 0 
    
Hydroxycinnamic acids (mg) 33 ± 0.4 1.7 ± 0 0 ± 0 
Vanillic acid  (µg) 0.5 ± 0.5 0 ± 0 0 ± 0 
p-coumaric (µg) 119 ± 17 3.5 ± 4 0 ± 0 
m-coumaric (µg) 28 ± 12 1.5 ± 1.5 0 ± 0 
o-coumaric (µg) 11 ± 4 0.5 ± 0.5 0 ± 0 
Caffeic acid (µg) 819 ± 22 125 ± 1.5 0 ± 0 
Dihydrocaffeic acid (µg) 25 ± 11 2.5 ± 6.5 0 ± 0 
Ferulic acid (µg) 84 ± 35 6.5 ± 4 0 ± 0 
Isoferulic acid (µg) 225 ± 150 17 ± 19 0 ± 0 
Neochlorogenic acid (µg) 8360 ± 374 425 ± 49 0 ± 0 
Chlorogenic acid (µg) 21341 ± 1180 1116 ± 50 0 ± 0 
Cryptochlorogenic (µg) 1746 ± 17 30 ± 2 0 ± 0 
    
Benzoic acids (mg) 2.8 ± 0 0.5 ± 0 0 ± 0 
Benzoic acid (µg) 295 ± 23 16 ± 17 0 ± 0 
Gallic acid (µg) 61 ± 15 1 ± 0.5 0 ± 0 
4-hydroxybenzoic acid (µg) 59 ± 1.5 23 ± 3 0 ± 0 
3-hydroxybenzoic acid (µg) 6.5 ± 7 0.5 ± 0.5 0 ± 0 
2-Hydroxybenzoic acid (µg) 25 ± 28 5 ± 5.5 0 ± 0 
Protocatechuic acid (µg) 2396 ± 105 450 ± 18 0 ± 0 
Phloretin (µg) 0.5 ± 0.5 0 ± 0 0 ± 0 
Epicatechin (µg) 101 ± 5.5 0 ± 0 0 ± 0 
    
Total phenolics (mg) 71 ± 1.5 4.8 ± 0.6 0 ± 0 
Anthocyanins (mg) 29 ± - 3.6 ± - 0 ± 0 
Proanthocyanidins (mg) 16 ± 3.2 3.3 ± 0.9 0 ± 0 
Total (poly)phenols (mg) 116 ± 4.7 12 ± 1.4 0 ± 0 
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Table 2. Baseline characteristics of the population included in the study. 
Population 
characteristics 
All 
(n=66) 
Extract 
(n=23) 
Whole fruit 
(n=23) 
Control 
(n=20) 
 Mean ± SD 
Age (years) 24 ± 5.3 24 ± 6.3 24 ± 5.2 23 ± 4.4 
Height (cm) 177 ± 7.2 178 ± 7.3 176 ± 5.9 176 ± 8.5 
Weight (Kg) 71 ± 8.3 74 ± 7.5 70 ± 9.8 69 ± 6.8 
BMI (kg/m2) 23 ± 2.1 23 ± 1.9 23 ± 2.6 22 ± 1.6 
PSBP (mmHg) 119 ± 10.6 119 ± 12.6 119 ± 8.4 118 ± 11 
PDBP (mmHg) 68 ± 7.9  67 ± 8.2 69 ± 9.1 68 ± 6.2 
CSBP (mmHg) 101 ± 7.9 101 ± 8.6 102 ± 8.3 100 ± 7 
CDBP (mmHg) 70 ± 9.2 69 ± 9.8 71 ± 10.1 70 ± 7.4 
HR (bpm) 62 ± 9.8 62 ± 11.4 63 ± 9.4 62 ± 8.9 
PWV (m/s) 5.5 ± 1.1 5.6 ± 1.2 5.7 ± 1.2 5.1 ± 1 
AIx (%) -3.6 ± 10  -4.4 ± 10.3 -2.6 ± 9.4 -3.8 ± 10.7 
Body fat (%) 15 ± 4.0 15 ± 3.9 14 ± 4.4 15 ± 3.4 
BMR (Kcal) 1787 ± 188 1848 ± 171 1770 ± 192 1736 ± 191 
PGLU (mmol/L) 5 ± 0.3 5 ± 0.3 5.0 ± 0.4 4.9 ± 0.3 
PLT (109/L) 225 ± 38.8 225 ± 46.1 221 ± 38 228 ± 31.9 
Urea (mmol/L) 5.8 ± 1.3 6.0 ± 1.5 5.5 ± 0.8 5.9 ± 1.5 
Creatin (mmol/L) 80 ± 10.2 84 ± 12.2 77 ± 7.7 77 ± 9 
ALP (IU/L) 66 ± 16.3 65 ± 14.3 63 ± 16.4 70 ± 18.4 
AST (IU/L) 26 ± 12.6 30 ± 18.5 24 ± 7.7 23 ± 6.7 
GGT (IU/L) 17 ± 14.4 19 ± 20.2 16 ± 11.3 17 ± 9.5 
CHOL (mmol/L) 4.1 ± 0.7 4.3 ± 0.7 4.0 ± 0.6 4.1 ± 0.8 
TRIG (mmol/L) 0.8 ± 0.4 1.0 ± 0.5 0.7 ± 0.3 0.8 ± 0.3 
HDL (mmol/L) 0.4 ± 0.3 1.3 ± 0.2 1.5 ± 0.3 1.3 ± 0.2 
LDL (mmol/L) 2.4 ± 0.6 2.5 ± 0.6 2.2 ± 0.5 2.4 ± 0.8 
LDH (IU/L) 150 ± 22.9 156 ± 17 147 ± 27.6 147 ± 22.6 
Smoking (%) 14 ± 5.6 9 13 20 
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Table 3. Plasma (poly)phenols correlation with FMD. 
 FMD vs  plasma 
(poly)phenols 
Aronia 
extract (2 h) 
(n=43) 
Aronia extract 
(12 wks) 
(n=43) 
Aronia extract 
(12 wks, 2 h) 
(n=43) 
Aronia whole fruit 
(12 wks, 2 h) 
(n=43) 
 Spearman ρ 
Total (poly)phenols 0.34    
2-Hydroxyhippuric acid 0.36    
Protocatechuic acid   0.41  
2-Hydroxybenzoic acid   0.30  
3-Hydroxybenzoic acid  0.30 0.41 0.38 
4-Hydroxybenzoic acid 0.35    
Vanillic acid-4'-O-sulfate 0.33    
Isovanillic acid  0.31   
Gallic acid   0.45  
Dihydroferulic acid 0.58    
Dihydro isoferulic acid 0.41    
p-Coumaric acid   0.30  
o-Coumaric acid    0.36 
Ferulic acid-4'-O-sulfate    0.32 
Isoferulic acid-3'-O-β-D-
glucuronide 
0.39    
Dihydroferulic acid-4'-O-
β-D-glucuronide 
0.32    
Dihydro isoferulic acid-
3'-O-β-D-glucuronide 
0.37    
Dihydro isoferulic acid-
3'-O-sulfate 
 0.35   
Phenylacetic acid 0.48  0.44 0.33 
3,4-
Dihydroxyphenylacetic 
acid 
   0.31 
4-Hydroxybenzaldehyde   0.39  
Catechol-O-sulfate 0.44    
Kaempferol   0.42  
Quercetin-3'-O-β-D-
glucuronide 
0.40    
(4R)-5-(3'-
Hydroxyphenyl)-γ-
valerolactone-4'-O-
sulfate 
0.39    
 
Correlations between changes in plasma metabolite concentrations (with respect to baseline) 
and FMD changes (with respect to baseline). Correlations were performed by correlating 
control and aronia extract outcomes in one analysis as a second indepent analysis was done 
using control and aronia whole fruit outcomes. This was repeated for data obtained from acute 
(2 h), chronic (12 wks) and acute on chronic (12 wks, 2 h) measurements. No correlations 
were found between aronia whole fruit and FMD on the acute and chronic level. Spearman 
was used for correlations of non-parametric data. All data represented had p < 0.05.  
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Figure Legends 
Figure 1. CONSORT study flow diagram and study design. A. Participant flowchart. 
B.  Study design. FMD, flow-mediated dilation; PWV, pulse wave velocity; AIX, 
augmentation index. 
Figure 2. Improvements in endothelial function measured as FMD after aronia 
consumption. A FMD change from baseline (CFB) three months after chronic 
consumption of the control (n=19), aronia whole fruit (n=20) or aronia extract (n=22) 
capsules. B. FMD change from baseline (CFB) 2h post-consumption of the control 
(n=19), aronia whole fruit (n=20) or aronia extract (n=22) capsules. C. FMD change 
from baseline (CFB) at 2h post-consumption and after three months chronic 
consumption of the control (n=19), aronia whole fruit (n=21) or aronia extract (n=22) 
capsules. 
Figure 3. Plasma (poly)phenol metabolites after consumption of aronia berries. 
Control (n=20), aronia whole fruit (n=23), aronia extract (n=23). 
Figure 3A. Total hippuric acids 
Figure 3B. Total benzoic acids 
Figure 3C. Total cinnamic acids 
Figure 3D. Total phenylacetic acids 
Figure 3E. Total benzaldehydes 
Figure 3F. Total catechols 
Figure 3G. Total pyrogallols 
Figure 3H. Total flavanols 
Figure 3I. Total propionic acids 
Figure 4. Changes in the gut microbiome associated to aronia treatments. Top 10 
features from aronia extract (A), aronia whole fruit (B) and control (C) data sets, as 
revealed by Random Forests. Red dots denote bacterial genera significantly 
discriminant of the final microbiome structure respect to the initial configuration for 
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each treatment. Differences in the relative abundances of each relevant genera were 
investigated using Wilcoxon signed-rank tests and visualized by both dot plots and 
box plots. Paired samples from the same individual were connected by a black line. 
Figure 5. Correlation heatmap of plasma metabolites and gut microbiome. A. 
Changes in metabolite concentrations (adjusted from control) versus changes in 
abundance of microbial genera (adjusted from control) upon 12-week consumption of 
aronia extract (n = 23). B. Changes in metabolite concentrations (adjusted from 
control) versus changes in abundance of microbial genera (adjusted from control) 
upon 12-week consumption of aronia whole fruit (n = 23). Correlations were performed 
in two independent analyses: A. aronia extract (adjusted from control) and B. aronia 
whole fruit (adjusted from control). Values are represented as spearman rho, *p < 0.05. 
